Nusinersen Sodium Patent Expiration
Nusinersen Sodium is Used for treating spinal muscular atrophy in infants and adults by increasing exon-7 inclusion in SMN2 mRNA. It was first introduced by Biogen Idec Inc
Nusinersen Sodium Patents
Given below is the list of patents protecting Nusinersen Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Spinraza | US12013403 | Compositions and methods for detection of SMN protein in a subject and treatment of a subject | Mar 04, 2036 | Biogen Idec |
| Spinraza | US10436802 | Methods for treating spinal muscular atrophy | Sep 11, 2035 | Biogen Idec |
| Spinraza | US9926559 | Compositions and methods for modulation of SMN2 splicing in a subject | Jan 09, 2034 | Biogen Idec |
| Spinraza | US8361977 | Compositions and methods for modulation of SMN2 splicing | Dec 23, 2030 | Biogen Idec |
| Spinraza | US8980853 | Compositions and methods for modulation of SMN2 splicing in a subject | Nov 24, 2030 | Biogen Idec |
| Spinraza | US9717750 | Compositions and methods for modulation of SMN2 splicing in a subject | Jun 17, 2030 | Biogen Idec |
| Spinraza | US7838657 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | Jul 11, 2027 | Biogen Idec |
| Spinraza | US10266822 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | Dec 05, 2025 | Biogen Idec |
| Spinraza | US8110560 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | Dec 05, 2025 | Biogen Idec |
| Spinraza | US7101993 | Oligonucleotides containing 2′-O-modified purines |
Sep 05, 2023
(Expired) | Biogen Idec |
| Spinraza | US6210892 | Alteration of cellular behavior by antisense modulation of mRNA processing |
Oct 07, 2018
(Expired) | Biogen Idec |
| Spinraza | US6166197 | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
Dec 26, 2017
(Expired) | Biogen Idec |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Nusinersen Sodium's patents.
Latest Legal Activities on Nusinersen Sodium's Patents
Given below is the list recent legal activities going on the following patents of Nusinersen Sodium.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Jun, 2024 | US8361977 |
| Email Notification Critical | 21 Mar, 2024 | US9717750 |
| Change in Power of Attorney (May Include Associate POA) Critical | 21 Mar, 2024 | US9717750 |
| Patent Term Extension Certificate Critical | 18 Mar, 2024 | US8361977 |
| Change in Power of Attorney (May Include Associate POA) Critical | 11 Mar, 2024 | US8361977 |
| Email Notification Critical | 11 Mar, 2024 | US8361977 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 05 Mar, 2024 | US8361977 |
| Change in Power of Attorney (May Include Associate POA) Critical | 29 Feb, 2024 | US10436802 |
| Email Notification Critical | 29 Feb, 2024 | US10436802 |
| Change in Power of Attorney (May Include Associate POA) Critical | 29 Feb, 2024 | US9926559 |
Nusinersen Sodium's Family Patents
